Machine learning to identify biomarkers of response to immunotherapy in KRAS wildtype (KRASwt) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I.
ALK, anaplastic lymphoma kinase; BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; irAE, ...
New CY Series is designed to achieve exceptional levels of inspection accuracy while maintaining high speed manufacturing. Antares Vision Group will offer live demonstrations of an integrated line ...
In the hallowed silence of the National Heroes Acre, names are etched in granite, preceded by a title that once commanded absolute reverence: “Doctor.” But as we peel back the layers of Zimbabwe’s ...
Good morning. My name is Rob, and I will be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions] I'd now like to introduce Beth DelGiacco, Vice ...
Despite immune checkpoint inhibitors(ICIs) significantly improve clinical outcomes in patients with advanced non-small cell lung cancer (aNSCLC), disease progression ...
Five-Year Survival Outcomes With Atezolizumab After Chemotherapy in Resected Stage IB-IIIA Non–Small Cell Lung Cancer (IMpower010): An Open-Label, Randomized, Phase III Trial In this global phase III ...
Journal of Nuclear Medicine June 2024, jnumed.124.267434; DOI: https://doi.org/10.2967/jnumed.124.267434 These aggregative approaches raise an interesting question ...
aDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key ...
This final rule is effective July 1, 2024. Phased-in implementation dates for required changes are addressed in the SUPPLEMENTARY INFORMATION section of this rule. This table of contents is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results